PCSK9 and familial hypercholesterolemia: Overall, since the pharmacologicalefficacy of inclisiran in LDL-C reduction is comparable to that of monoclonalantibodies against PCSK9, the longer effect duration and the favorable safetyprofile may favor this newer approach for hypercholesterolemia management.